CCL18 and breast cancer: However, M2 macrophages that were transfected with CCL18 siRNAs or treated with CCL18- neutralizing antibodies lost their ability to reduce miR98 expression in both breast cancer cell lines (P < 0.05) (Figure 1D, 1E).